Co-Diagnostics, Inc. Awarded Funding for Co-Dx PCR Home Platform from NIH RADx® Tech Program
- Dow touches 2023 peak as investors eye end of robust November
- JPMorgan sees 8% downside risk for S&P 500 next year
- Salesforce shares jump premarket after cloud software firm lifts annual guidance
- Fed's preferred inflation gauge slows to 3.0% annually in October
- Stocks edge lower as dollar, Treasury yields rise with rates in focus
The Company intends to use the funds awarded by the National Institutes of Health for completion of its upper respiratory panel multiplex on Co-Dx PCR Home™ platform
Co-Diagnostics will utilize the funds from the RADx Tech award to complete development of its flu A/B, COVID-19, and RSV multiplex test, preparatory for that test to begin clinical trials on the Co-Dx PCR Home. The Co-Dx PCR Home is currently undergoing clinical evaluations in anticipation of its submission to the FDA and an initial product launch for a COVID-19 test.
"We are pleased that the innovation and potential of our new Co-Dx PCR Home platform has been recognized by the highly competitive RADx Tech program, with its focus on accessibility and ease of use for over-the-counter and point-of-care COVID-19 diagnostic solutions," remarked
"Our mission to improve the quality of life through making high-quality, affordable diagnostics more available worldwide will be one step closer with the completion of this in-demand respiratory multiplex, which we believe meets the NIH's standards for increased accessibility of next-generation testing as we navigate this post-pandemic landscape."
The NIH launched the RADx initiative on
This project has been funded in part with federal funds from the National Institute of Biomedical Imaging (NIBIB), National Institutes of Health, Department of Health and Human Services, under Contract No. 75N92023D00001.
The Co-Dx PCR Home testing platform and its associated tests are subject to FDA review and are not available for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc, a
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) that are subject to a number of risks and uncertainties. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include statements regarding completion of our upcoming upper respiratory panel on the Company's Co-Dx PCR Home™ testing platform, initiation of clinical trials on the Co-Dx PCR Home in the upcoming flu season, and our belief our platform will meet the NIH's standards for increased accessibility of next-generation testing. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in our Risk Factors disclosure in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on
View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-awarded-funding-for-co-dx-pcr-home-platform-from-nih-radx-tech-program-301876458.html
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Weibo (WB) Prices Offering of $300 Million Convertible Senior Notes
- Weibo (WB) Announces Proposed Offering of American Depositary Shares in connection with the Delta Placement of Borrowed ADSs
- Taylor Swift's Autographed Guitar Strikes a Chord for Homeownership in Underserved Communities
Create E-mail Alert Related CategoriesPRNewswire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!